Online inquiry

IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14720MR)

This product GTTS-WQ14720MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets SELP gene. The antibody can be applied in Sickle Cell Disease (SCD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_003005.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6403
UniProt ID P16109
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ14720MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2611MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG 557
GTTS-WQ6596MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DC-1728001
GTTS-WQ4402MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-224818
GTTS-WQ11208MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ3159MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AR-101
GTTS-WQ2053MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AH-PD1
GTTS-WQ2513MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 334
GTTS-WQ14320MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RG7414
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW